Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan;92(1):22-27.
doi: 10.4269/ajtmh.14-0298. Epub 2014 Nov 10.

Performance of BinaxNOW G6PD deficiency point-of-care diagnostic in P. vivax-infected subjects

Lyda Osorio, Nick Carter, Preetam Arthur, Germana Bancone, Sowmya Gopalan, Sandeep K Gupta, Harald Noedl, Sanjay K Kochar, Dhanpat K Kochar, Srivicha Krudsood, Marcus V Lacerda, Alejandro Llanos-Cuentas, Ronnatrai Rueangweerayut, Ramadurai Srinivasan, Moritz Treiber, Jörg J Möhrle, Justin Green

Performance of BinaxNOW G6PD deficiency point-of-care diagnostic in P. vivax-infected subjects

Lyda Osorio et al. Am J Trop Med Hyg. 2015 Jan.

Abstract

Accurate diagnosis of glucose-6-phosphate dehydrogenase (G6PD) deficiency is required to avoid the risk of acute hemolysis associated with 8-aminoquinoline treatment. The performance of the BinaxNOW G6PD test compared with the quantitative spectrophotometric analysis of G6PD activity was assessed in 356 Plasmodium vivax-infected subjects in Brazil, Peru, Thailand, and India. In the quantitative assay, the median G6PD activity was 8.81 U/g hemoglobin (range = 0.05-20.19), with 11 (3%) subjects identified as deficient. Sensitivity of the BinaxNOW G6PD to detect deficient subjects was 54.5% (6 of 11), and specificity was 100% (345 of 345). Room temperatures inadvertently falling outside the range required to perform the rapid test (18-25°C) together with subtlety of color change and insufficient training could partially explain the low sensitivity found. Ensuring safe use of 8-aminoquinolines depends on additional development of simple, highly sensitive G6PD deficiency diagnostic tests suitable for routine use in malaria-endemic areas.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Diagram of study participants. QC = quality control.
Figure 2.
Figure 2.
Distribution of G6PD activity (percentage of the normal value in the reference population) according to the quantitative assay by sex.
Figure 3.
Figure 3.
Distribution of G6PD activity according to the BinaxNOW G6PD results.
See this image and copyright information in PMC

References

    1. Battle KE, Gething PW, Elyazar IR, Moyes CL, Sinka ME, Howes RE, Guerra CA, Price RN, Baird KJ, Hay SI. The global public health significance of Plasmodium vivax. Adv Parasitol. 2012;80:1–111. - PubMed
    1. World Health Organization . Guidelines for the Treatment of Malaria. Geneva: WHO Press; 2010.
    1. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, Arthur P, Chuenchom N, Möhrle JJ, Duparc S, Ugwuegbulam C, Kleim JP, Carter N, Green JA, Kellam L. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2013;383:1049–1058. - PubMed
    1. Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, Hogg MM, Battle KE, Padilla CD, Baird JK, Hay SI. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9:e1001339. - PMC - PubMed
    1. Burgoine KL, Bancone G, Nosten F. The reality of using primaquine. Malar J. 2010;9:376. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources